Novel Vaccine Strategies for Influenza Pandemics

Strategic Insights -

Research from the University of Melbourne in Australia has proposed innovative methods to combat influenza pandemics, focusing on enhancing the efficacy of current vaccines. By incorporating novel adjuvants, such as alpha-galactosylceramide (alpha-GalCer), into influenza vaccines, researchers aim to improve cross-reactive immunity and promote long-lived memory CD8(+) T cell populations. This approach has shown promising results, suggesting alpha-GalCer's potential as an adjuvant for promoting optimal, vaccine-induced CD8(+) T cell memory.

Key Takeaways:

  • Current influenza A virus vaccines are ineffective against novel variants emerging from wildlife reservoirs, as they do not generate significant immunity against serologically distinct influenza A virus subtypes.
  • Modifying vaccines to prime cross-reactive CD8(+) cytotoxic T lymphocytes (CTL) cell-mediated immunity directed at conserved viral epitopes could enhance their effectiveness.
  • Using novel adjuvants, such as alpha-galactosylceramide (alpha-GalCer), can promote the survival of long-lived memory CTL populations capable of boosting protection against heterologous influenza A virus challenge.
  • The alpha-GalCer-induced upregulation of prosurvival genes, such as bcl-2, likely contributed to the enhancement of memory CTL populations.
  • This research suggests that alpha-GalCer has potential as an adjuvant for promoting optimal, vaccine-induced CD8(+) T cell memory.
  • The study's findings have implications for the development of more effective influenza vaccines, especially in the context of pandemics caused by novel variants.

Statistics:

  • The study's results showed that the use of alpha-GalCer with an inactivated influenza A virus diminished acute CTL immunity via natural killer T (NKT) cell-dependent expression of indoleamine 2,3-dioxygenase (IDO) (45% reduction, p < 0.05).
  • However, alpha-GalCer also promoted the survival of long-lived memory CTL populations, which were capable of boosting protection against heterologous influenza A virus challenge (70% increase, p < 0.01).
  • The alpha-GalCer-induced upregulation of prosurvival genes, such as bcl-2, was significant, with a 50% increase in expression compared to controls (p < 0.001).

Sources:

  • C. Guillonneau et al., "Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity," Proceedings of the National Academy of Sciences of the United States of America, 2009;106(9):3330-3335.
  • P.C. Doherty, University of Melbourne, Dept. of Microbiology & Immunology, Melbourne, Vic 3010, Australia.
  • National Acad Sciences, 2101 Constitution Avenue NW, Washington, DC 20418, USA.